Small nucleic acid therapies are heating up again

A wave of major deals—including Novartis's $12B acquisition of Avidity Biosciences and Eli Lilly's $1.2B collaboration with SanegeneBio—signals strong confidence in the sector's revival, driven by breakthroughs in delivery tech and new therapeutic applications.

With China's R&D advancing to the global forefront, industry insiders predict a phase of rapid growth within the next 2–3 years.

Dive into the data and trends shaping this resurgence in our latest analysis: Small nucleic acid therapies heat up again, driven by dual breakthroughs